Investig Clin Urol.  2016 Sep;57(5):307-308. 10.4111/icu.2016.57.5.307.

Liquid biopsy? A recent breakthrough in noninvasive bladder cancer surveillance

• Kang M
• Ku JH

• KMID: 2427007
• DOI: http://doi.org/10.4111/icu.2016.57.5.307

Abstract

No abstract available.

MeSH Terms

Biomarkers, Tumor/metabolism
Cell-Free Nucleic Acids/metabolism
DNA, Neoplasm/metabolism
Early Detection of Cancer/methods
Humans
Liquid Biopsy/methods
RNA, Neoplasm/metabolism
Urinary Bladder/*pathology
Urinary Bladder Neoplasms/*pathology
Biomarkers, Tumor
Cell-Free Nucleic Acids
DNA, Neoplasm
RNA, Neoplasm

Reference

1. Kim WJ. Changing landscape of diagnosis and treatment of bladder cancer. Investig Clin Urol. 2016; 57:Suppl 1. S1–S3.

2. Ma M, Zhu H, Zhang C, Sun X, Gao X, Chen G. "Liquid biopsy"-ctDNA detection with great potential and challenges. Ann Transl Med. 2015; 3:235.

3. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6:224ra24.

4. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med. 2014; 20:548–554.

5. Birkenkamp-Demtröder K, Nordentoft I, Christensen E, Hoyer S, Reinert T, Vang S, et al. Genomic alterations in liquid biopsies from patients with bladder cancer. Eur Urol. 2016; 70:75–82.

6. Kim YH, Yan C, Lee IS, Piao XM, Byun YJ, Jeong P, et al. Value of urinary topoisomerase-IIA cell-free DNA for diagnosis of bladder cancer. Investig Clin Urol. 2016; 57:106–112.

7. Ilie M, Hofman V, Long E, Bordone O, Selva E, Washetine K, et al. Current challenges for detection of circulating tumor cells and cell-free circulating nucleic acids, and their characterization in non-small cell lung carcinoma patients. What is the best blood substrate for personalized medicine? Ann Transl Med. 2014; 2:107.